Capecitabine combined with oxaliplatin (CapOx) in clinical practice: how significant is peripheral neuropathy?
| Autor: | Dawn J Storey, Hamish A. Phillips, Sally Clive, Lucy Wall, Chelsea M. McLean, Marie Fallon, L K Dawson, M Sakala |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Adult
medicine.medical_specialty Palliative care Organoplatinum Compounds Colorectal cancer medicine.medical_treatment Deoxycytidine Gastroenterology Capecitabine Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Adverse effect Aged Retrospective Studies Chemotherapy business.industry Incidence Peripheral Nervous System Diseases Hematology Middle Aged medicine.disease Oxaliplatin Surgery Peripheral neuropathy Scotland Oncology Fluorouracil business medicine.drug |
| Zdroj: | Annals of Oncology. 21:1657-1661 |
| ISSN: | 0923-7534 |
| DOI: | 10.1093/annonc/mdp594 |
| Popis: | Background There is speculation that peripheral neuropathy (PN) with capecitabine and oxaliplatin (CapOx; 130 mg/m2, day 1, every 21 days) may be more common than with FOLFOX4 (5-fluorouracil and oxaliplatin 85 mg/m2, day 1, every 14 days). We aimed to determine PN incidence and associations during CapOx, and 6 and 12 months after CapOx. Patients and methods Retrospective audit of 188 oxaliplatin-naive colorectal cancer patients (87 adjuvant, 101 palliative) who received at least one cycle of CapOx. Neurosensory Common Toxicity Criteria Adverse Events version 3 were applied. Results Overall, 94% experienced acute PN. Worst severities for adjuvant and palliative patients, respectively, were grade 1, 44% and 54%; grade 2, 35% and 32%; grade 3, 16% and 3%; grade 4, 0% and 1% and grade unclear 1% and 1%. Two patients developed PN after CapOx completion despite no symptoms during treatment. Chronic PN at 6 months affected 57% and 18% of adjuvant and palliative patients, respectively. At 12 months, 35% and 16% were affected. Chronic PN at 12 months was associated with cumulative oxaliplatin dose but not age, gender, acute myotonia, pseudolaryngospasm or grade 2 or more PN during treatment. Conclusion Incidence of acute PN during CapOx appears similar to FOLFOX4 but chronic PN in adjuvant patients may be more common with CapOx. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|